Both in Pharmaceuticals
Perspective Therapeutics vs Evommune
Over the past year CATX returned +17.5% and EVMN returned −58.7%; their daily moves had a correlation of 0.07.
CATX +17.5% EVMN −58.7%Growth of $1, one year, split-adjusted
| Metric | CATX | EVMN |
|---|---|---|
| Price | $2.62 | $8.35 |
| Market cap | $299.1M | $303.0M |
| Today | +4.80% | −0.48% |
| 1 month | −15.8% | −36.9% |
| 6 months | −31.6% | −62.0% |
| Year to date | −4.7% | −51.2% |
| 1 year | −22.9% | — |
| Revenue growth (YoY) | −72.1% | — |
| Gross margin | 100.0% | — |
| Net margin | −33069.1% | — |
| P/E (TTM) | — | — |
| Price / sales | 731.2× | — |
| Net cash | $235.3M | $200.4M |
| Dividend yield | — | — |
| Volatility (60d) | 62.1% | 74.5% |
| Short % of float | 24.0% | 12.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).